Risk factors and outcomes of anxiety symptom trajectories in type 2 diabetes: the Fremantle Diabetes Study Phase II
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Risk factors and outcomes of anxiety symptom trajectories in type 2 diabetes : the Fremantle Diabetes Study Phase II. / Whitworth, S. R.; Bruce, D. G.; Starkstein, S. E.; Davis, T. M.E.; Skinner, T. C.; Davis, W. A.; Bucks, R. S.
I: Diabetic Medicine, Bind 37, Nr. 10, 2020, s. 1688-1695.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Risk factors and outcomes of anxiety symptom trajectories in type 2 diabetes
T2 - the Fremantle Diabetes Study Phase II
AU - Whitworth, S. R.
AU - Bruce, D. G.
AU - Starkstein, S. E.
AU - Davis, T. M.E.
AU - Skinner, T. C.
AU - Davis, W. A.
AU - Bucks, R. S.
PY - 2020
Y1 - 2020
N2 - Aim: To identify determinants and outcomes of 4-year trajectories of anxiety symptoms in a community-based cohort with type 2 diabetes. Methods: Some 1091 participants in the Fremantle Diabetes Study-Phase II with type 2 diabetes completed the Generalized Anxiety Disorder Scale at baseline and biennially for 4 years, in addition to psychological, biomedical and self-management measures. Latent growth mixture modelling identified trajectories of anxiety symptom severity, and regression models determined predictors of trajectory membership and associated outcomes. Results: Two distinct groups of participants were identified: those with continuously low–no anxiety symptoms (87%) and those with improving but consistently high anxiety symptoms (elevated anxiety; 13%). Higher HbA1c and BMI, macrovascular complications and a history of generalized anxiety and/or major depressive disorder increased the risk of elevated anxiety. Elevated anxiety did not predict change in health-related outcomes over time. Elevated anxiety and depression symptoms were highly comorbid and those with both displayed the most persistent anxiety symptoms. Conclusions: A subgroup of individuals with type 2 diabetes are at risk of persistently elevated anxiety symptoms. Routine monitoring of the severity of psychological symptoms over time in this population should facilitate earlier and more intensive mood management.
AB - Aim: To identify determinants and outcomes of 4-year trajectories of anxiety symptoms in a community-based cohort with type 2 diabetes. Methods: Some 1091 participants in the Fremantle Diabetes Study-Phase II with type 2 diabetes completed the Generalized Anxiety Disorder Scale at baseline and biennially for 4 years, in addition to psychological, biomedical and self-management measures. Latent growth mixture modelling identified trajectories of anxiety symptom severity, and regression models determined predictors of trajectory membership and associated outcomes. Results: Two distinct groups of participants were identified: those with continuously low–no anxiety symptoms (87%) and those with improving but consistently high anxiety symptoms (elevated anxiety; 13%). Higher HbA1c and BMI, macrovascular complications and a history of generalized anxiety and/or major depressive disorder increased the risk of elevated anxiety. Elevated anxiety did not predict change in health-related outcomes over time. Elevated anxiety and depression symptoms were highly comorbid and those with both displayed the most persistent anxiety symptoms. Conclusions: A subgroup of individuals with type 2 diabetes are at risk of persistently elevated anxiety symptoms. Routine monitoring of the severity of psychological symptoms over time in this population should facilitate earlier and more intensive mood management.
U2 - 10.1111/dme.14344
DO - 10.1111/dme.14344
M3 - Journal article
C2 - 32531090
AN - SCOPUS:85087289327
VL - 37
SP - 1688
EP - 1695
JO - Diabetic Medicine
JF - Diabetic Medicine
SN - 0742-3071
IS - 10
ER -
ID: 244972873